{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Solution+Placebo", "query": { "intervention": "IV Solution Placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1070, "total_pages": 107, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Solution+Placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T17:27:07.910Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02530905", "title": "Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "SRP-4045", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sarepta Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "21 Years", "sex": "MALE", "summary": "7 Years to 21 Years · Male only" }, "enrollment_count": 12, "start_date": "2015-10-08", "completion_date": "2018-10-03", "has_results": true, "last_update_posted_date": "2021-05-17", "last_synced_at": "2026-09-05T17:27:07.910Z", "location_count": 3, "location_summary": "Los Angeles, California • Chicago, Illinois • Baltimore, Maryland", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02530905" }, { "nct_id": "NCT06053814", "title": "NS-050/NCNP-03 in Boys With DMD (Meteor50)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Duchenne Muscular Dystrophy" ], "interventions": [ { "name": "NS-050/NCNP-03", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NS Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "15 Years", "sex": "MALE", "summary": "4 Years to 15 Years · Male only" }, "enrollment_count": 20, "start_date": "2024-09-18", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-09-05T17:27:07.910Z", "location_count": 6, "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06053814" }, { "nct_id": "NCT04570384", "title": "Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Hypoxemic Respiratory Failure" ], "interventions": [ { "name": "L-Citrulline", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Asklepion Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 65, "start_date": "2020-10-15", "completion_date": "2021-09-30", "has_results": true, "last_update_posted_date": "2023-02-22", "last_synced_at": "2026-09-05T17:27:07.910Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04570384" }, { "nct_id": "NCT02614547", "title": "A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Severe Postpartum Depression" ], "interventions": [ { "name": "SAGE-547", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Supernus Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 21, "start_date": "2015-12-15", "completion_date": "2016-06-22", "has_results": true, "last_update_posted_date": "2025-09-15", "last_synced_at": "2026-09-05T17:27:07.910Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Worcester, Massachusetts • Chapel Hill, North Carolina + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02614547" }, { "nct_id": "NCT02734147", "title": "High Dose Intravenous Ascorbic Acid in Severe Sepsis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sepsis" ], "interventions": [ { "name": "Ascorbic Acid", "type": "DRUG" }, { "name": "Normal Saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Christiana Care Health Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-04-01", "completion_date": "2017-11-23", "has_results": true, "last_update_posted_date": "2021-02-16", "last_synced_at": "2026-09-05T17:27:07.910Z", "location_count": 1, "location_summary": "Newark, Delaware", "locations": [ { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT02734147" }, { "nct_id": "NCT03615326", "title": "Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Neoplasms", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "S-1", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 738, "start_date": "2018-10-05", "completion_date": "2025-11-12", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-05T17:27:07.910Z", "location_count": 23, "location_summary": "Los Angeles, California • Monterey, California • Orange, California + 19 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03615326" }, { "nct_id": "NCT04912115", "title": "Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dyskinesias", "Movement Disorders", "Central Nervous System Diseases", "Nervous System Diseases", "Neurologic Manifestations" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PharmaTher Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "30 Years to 85 Years" }, "enrollment_count": 30, "start_date": "2021-10-05", "completion_date": "2024-03-30", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-09-05T17:27:07.910Z", "location_count": 7, "location_summary": "Tucson, Arizona • Chula Vista, California • Fountain Valley, California + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04912115" }, { "nct_id": "NCT01115920", "title": "Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "MTP-131 (Bendavia™)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stealth BioTherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2010-05", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2010-11-18", "last_synced_at": "2026-09-05T17:27:07.910Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01115920" }, { "nct_id": "NCT04623242", "title": "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Alzheimers Disease", "Dementia", "Alzheimers Disease, Familial" ], "interventions": [ { "name": "Gantenerumab", "type": "DRUG" }, { "name": "Solanezumab", "type": "DRUG" }, { "name": "Matching Placebo (Gantenerumab)", "type": "DRUG" }, { "name": "Matching Placebo (Solanezumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 194, "start_date": "2012-12", "completion_date": "2020-03-06", "has_results": true, "last_update_posted_date": "2022-09-22", "last_synced_at": "2026-09-05T17:27:07.910Z", "location_count": 10, "location_summary": "Birmingham, Alabama • La Jolla, California • New Haven, Connecticut + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04623242" }, { "nct_id": "NCT02468674", "title": "A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcopenia" ], "interventions": [ { "name": "bimagrumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 160, "start_date": "2015-07-22", "completion_date": "2018-12-03", "has_results": true, "last_update_posted_date": "2020-06-16", "last_synced_at": "2026-09-05T17:27:07.910Z", "location_count": 5, "location_summary": "Miami Lakes, Florida • Gainesville, Georgia • Spartanburg, South Carolina + 2 more", "locations": [ { "city": "Miami Lakes", "state": "Florida" }, { "city": "Gainesville", "state": "Georgia" }, { "city": "Spartanburg", "state": "South Carolina" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02468674" } ] }